Summary
Vertex Pharmaceuticals reported strong revenue growth in the first quarter of 2021, with total revenues increasing by 14% year-over-year to $1.724 billion. This growth was primarily driven by the strong performance of TRIKAFTA/KAFTRIO, particularly its uptake in Europe, and continued solid performance in the U.S. Net income also saw a healthy increase of 8% to $653.1 million, or $2.49 per diluted share. The company continues to invest heavily in research and development, with a focus on expanding its pipeline beyond cystic fibrosis into areas like sickle cell disease, type 1 diabetes, and pain management. Significant upcoming expenditures include a $900 million upfront payment to CRISPR Therapeutics related to the CTX001 gene therapy collaboration. Financially, Vertex maintains a robust liquidity position with $6.9 billion in cash, cash equivalents, and marketable securities. The company also completed its $500 million share repurchase program during the quarter. While the company faces ongoing research and development uncertainties and the potential for significant future expenditures, its strong revenue growth, solid profitability, and healthy balance sheet position it well for continued investment in its pipeline and future growth.
Financial Highlights
48 data points| Revenue | $1.72B |
| Cost of Revenue | $192.30M |
| Gross Profit | $1.53B |
| R&D Expenses | $456.00M |
| SG&A Expenses | $192.10M |
| Operating Expenses | $836.50M |
| Operating Income | $887.80M |
| Net Income | $653.10M |
| EPS (Basic) | $2.52 |
| EPS (Diluted) | $2.49 |
| Shares Outstanding (Basic) | 259.40M |
| Shares Outstanding (Diluted) | 261.90M |
Key Highlights
- 1Total revenues increased by 14% to $1.724 billion for the three months ended March 31, 2021, compared to $1.515 billion for the same period in 2020.
- 2Net income grew by 8% to $653.1 million ($2.49 per diluted share) for the three months ended March 31, 2021, from $602.8 million ($2.29 per diluted share) in the prior year.
- 3Product revenues were driven by TRIKAFTA/KAFTRIO, which saw a 33% increase, while other CF products experienced declines as patients switched to the newer therapy.
- 4The company is significantly expanding its pipeline, with ongoing clinical trials in areas beyond cystic fibrosis, including sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency, APOL1-mediated kidney diseases, and pain.
- 5Vertex entered into an amended collaboration with CRISPR Therapeutics for CTX001, involving a $900 million upfront payment and a 60/40 profit/loss split, positioning Vertex to lead global development and commercialization.
- 6The company maintained a strong liquidity position with $6.9 billion in cash, cash equivalents, and marketable securities as of March 31, 2021.
- 7Research and development expenses increased by 2% to $456.0 million, reflecting continued investment in pipeline expansion and clinical trials.